Tenofovir to Prevent HBV Reactivation

Official Title

A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia


The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's Lymphoma or CLL/SLL. The rate of re-activation will be compared between patients who receive preemptive tenofovir and patients who receive tenofovir as needed.

Trial Description

Primary Outcome:

  • Rate of reverse seroconversion
Secondary Outcome:
  • Rates of HBV Reactivation
  • Severe HBV-associated hepatitis
  • HBV-related liver failure
  • Liver-related death
  • Treatment-related adverse effects (AEs)
  • Time to start chemotherapy
  • Chemotherapy interruption
  • All-cause mortality

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society